Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18601247 | 0.95 | CYP1A2 (0.57) | HRH1CYP1A2CYP2C19SMN1; SMN2NAAA | |
| SCHEMBL289899 | 0.89 | HRH1 (0.53) | HRH1CYP1A2CYP2C19SMN1; SMN2CA12 | |
| SCHEMBL726512 | 0.81 | HRH1 (0.76) | HRH1CYP1A2CYP2C19SMN1; SMN2NAAA | |
| SCHEMBL9658041 | 0.81 | SMN1; SMN2 (0.61) | HRH1CYP1A2CYP2C19SMN1; SMN2NAAA | |
| SCHEMBL2843489 | 0.79 | HRH1 (0.80) | HRH1CYP1A2CYP2C19SMN1; SMN2NAAA | |
| SCHEMBL31040594 | 0.79 | HRH1 (0.80) | HRH1CYP1A2CYP2C19SMN1; SMN2NAAA | |
| Hydrochloric Acid SCHEMBL5827595 | 0.79 | HRH1 (0.73) | HRH1CYP1A2CYP2C19SMN1; SMN2NAAA | |
| SCHEMBL659243 | 0.79 | HRH1 (0.80) | HRH1CYP1A2CYP2C19SMN1; SMN2NAAA | |
| SCHEMBL4418086 | 0.79 | HRH1 (0.80) | HRH1CYP1A2CYP2C19SMN1; SMN2NAAA | |
| SCHEMBL11734076 | 0.79 | HRH1 (0.80) | HRH1CYP1A2CYP2C19SMN1; SMN2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118847-A1 | MODIFIELD ANTIBODIES TO PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF | CORNELL RESEARCH FOUNDATION, INC. | 2018-05-03 | — | — | US | disclosed |
| US-20170037142-A1 | METHODS OF TREATING PROSTATE CANCER WITH ANTI-PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODIES | BANDER NEIL H (US) | 2017-02-09 | — | — | US | disclosed |
| US-8653238-B2 | Compositions and methods for transport of molecules with enhanced release properties across biological barriers | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-02-18 | — | — | US | disclosed |
| US-20100278726-A1 | Modified Antibodies to Prostate-Specific Membrane Antigen and Uses Thereof | CORNELL RESEARCH FOUNDATION, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100255499-A1 | COMPOSITIONS AND METHODS FOR TRANSPORT OF MOLECULES WITH ENHANCED RELEASE PROPERTIES ACROSS BIOLOGICAL BARRIERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-10-07 | — | — | US | disclosed |
| EP-1599228-B1 | MODIFIED ANTIBODIES TO PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF | CORNELL RES FOUNDATION INC (US) | 2010-04-28 | — | — | EP | disclosed |
| US-7666414-B2 | Using modified anti-PSMA antibodies, or fragments thereof, to bind to human PSMA with high affinity and specificity; can be used as diagnostic, prophylactic, or therapeutic agents in vivo and in vitro | CORNELL RESEARCH FOUNDATION, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090280120-A1 | METHODS OF TREATING PROSTATE CANCER WITH ANTI-PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODIES | US ARMY, SECRETARY OF THE ARMY | 2009-11-12 | — | — | US | disclosed |
| US-7514078-B2 | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies | CORNELL RESEARCH FOUNDATION, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1988911-A2 | COMPOSITIONS AND METHODS FOR TRANSPORT OF MOLECULES WITH ENHANCED RELEASE PROPERTIES ACROSS BIOLOGICAL BARRIERS | The Board Of Trustees Of The University Of the Leland Stanford Junior University (US) | 2008-11-12 | — | — | EP | disclosed |
| EP-1599228-A4 | MODIFIED ANTIBODIES TO PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF | CORNELL RES FOUNDATION INC (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060088539-A1 | Modified antibodies to prostate-specific membrane antigen and uses thereof | US GOVERNMENT - SECRETARY FOR THE ARMY | 2006-04-27 | — | — | US | disclosed |
| US-20060062793-A1 | Modified antibodies to prostate-specific membrane antigen and uses thereof | US ARMY, SECRETARY OF THE ARMY | 2006-03-23 | — | — | US | disclosed |
| EP-1610818-A1 | MODIFIED ANTIBODIES TO PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-01-04 | — | — | EP | disclosed |
| EP-1599228-A2 | MODIFIED ANTIBODIES TO PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-30 | — | — | EP | disclosed |
| WO-2005094882-A1 | MODIFIED ANTIBODIES TO PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2004098535-A9 | MODIFIED ANTIBODIES TO PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2005-02-24 | — | — | WO | disclosed |
| WO-2004098535-A2 | MODIFIED ANTIBODIES TO PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040120958-A1 | Modified antibodies to prostate-specific membrane antigen and uses thereof | US GOVERNMENT - SECRETARY OF THE ARMY | 2004-06-24 | — | — | US | disclosed |
| US-20020013485-A1 | Cytotoxic agents comprising taxanes and their therapeutic use | IMMUNOGEN, INC. | 2002-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013485-A1 | Cytotoxic agents comprising taxanes and their therapeutic use | TP53, MCL1, TOP1 | HRH1 4093/4885CYP1A2 4748/4885CYP2C19 4683/4885 |
| US-20180118847-A1 | MODIFIELD ANTIBODIES TO PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF | KLK3, FOLH1, PSMA1 | HRH1 3633/4885CYP1A2 4876/4885CYP2C19 4856/4885 |
| US-20100278726-A1 | Modified Antibodies to Prostate-Specific Membrane Antigen and Uses Thereof | KLK3, FOLH1, PSMA6 | HRH1 3133/4885CYP1A2 4880/4885CYP2C19 4857/4885 |
| US-20170037142-A1 | METHODS OF TREATING PROSTATE CANCER WITH ANTI-PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODIES | KLK3, FOLH1, PSMA6 | HRH1 3463/4885CYP1A2 4879/4885CYP2C19 4850/4885 |
| US-20060062793-A1 | Modified antibodies to prostate-specific membrane antigen and uses thereof | KLK3, FOLH1, PSMA6 | HRH1 3133/4885CYP1A2 4880/4885CYP2C19 4857/4885 |
| US-20090280120-A1 | METHODS OF TREATING PROSTATE CANCER WITH ANTI-PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODIES | KLK3, FOLH1, PSMA6 | HRH1 3463/4885CYP1A2 4879/4885CYP2C19 4850/4885 |
| US-20060088539-A1 | Modified antibodies to prostate-specific membrane antigen and uses thereof | KLK3, FOLH1, PSMA6 | HRH1 3133/4885CYP1A2 4880/4885CYP2C19 4857/4885 |
| US-20100255499-A1 | COMPOSITIONS AND METHODS FOR TRANSPORT OF MOLECULES WITH ENHANCED RELEASE PROPERTIES ACROSS BIOLOGICAL BARRIERS | SLC2A9, SLC43A1, SLC2A8 | HRH1 3268/4885CYP1A2 4472/4885CYP2C19 4027/4885 |
| US-20040120958-A1 | Modified antibodies to prostate-specific membrane antigen and uses thereof | KLK3, FOLH1, PSMA6 | HRH1 3133/4885CYP1A2 4880/4885CYP2C19 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.